The tumor microenvironment (TME) in GBM is a major source of IFN and TNF ligand production and has been shown to contribute to therapy resistance as well as acquisition of a more aggressive phenotype with mesenchymal features [48]. This evidence concerns the gene IFNA1 and neoplasm.